Progressive multiple sclerosis

Current Opinion in Neurology

Volumn 28, Issue 3, 2015, Pages 237-243

  Ontaneda, Daniel ^a   Fox, Robert J ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials; multiple sclerosis; primary progressive; secondary progressive

Indexed keywords

FINGOLIMOD; GLATIRAMER; IBUDILAST; IMMUNOMODULATING AGENT; OCRELIZUMAB; RITUXIMAB; SIMVASTATIN; SIPONIMOD;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; REVIEW; ANIMAL; FACTUAL DATABASE; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA;

ANIMALS; DATABASES, FACTUAL; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS;

EID: 84929459738     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000195     Document Type: Review

References (53)

1. Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 2012; 63:389-404.
2. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998; 18:337-349.
3. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647-656.
4. Lassmann H. Multiple sclerosis: is there neurodegeneration independent from inflammation? J Neurol Sci 2007; 259 (1-2):3-6.
5. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31:247-269.
6. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157:267-276.
7. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14:164-174.
8. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135 (Pt 10):2925-2937.
9. Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999; 52:839-845.
10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
11. Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 2014; 20:1654-1657.
12. Koch MW, Greenfield J, Javizian O, et al. The natural history of early versus late disability accumulation in primary progressive MS. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print]
13. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83:278-286.
14. Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14:58.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452.
16. Palace J, Robertson N. Modifying disability in progressive multiple sclerosis. Lancet 2014; 383:2189-2191.
17. Lamers I, Feys P. Assessing upper limb function in multiple sclerosis. Mult Scler 2014. [Epub ahead of print]
18. Brissart H, Sauvee M, Latarche C, et al. Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis. Eur Neurol 2010; 64:345-350.
19. Kragt JJ, Thompson AJ, Montalban X, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008; 70 (13 Pt 2):1084-1091.
20. Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the multiple sclerosis functional composite. Mult Scler 2009; 15:984-997.
21. Rudick RA, Larocca N, Hudson LD; MSOAC. Multiple sclerosis outcome assessments consortium: genesis and initial project plan. Mult Scler 2014; 20:12-17.
22. Ontaneda D, Larocca N, Coetzee T, Rudick R. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) task force on clinical disability measures. Mult Scler 2012; 18:1074-1080.
23. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebocontrolled multicenter trial. Ann Neurol 2009; 66:460-471.
24. Suhy J, Rooney WD, Goodkin DE, et al. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000; 6:148-155.
25. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119 (Pt 6):2009-2019.
26. Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005; 26:341-346.
27. BoL, VedelerCA, Nyland HI, et al.Subpialdemyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003; 62:723-732.
28. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998; 51:234-238.
29. Schlaeger R, Papinutto N, Panara V, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014; 76:568-580.
30. Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 2007; 130 (Pt 8):2211-2219.
31. Pulicken M, Gordon-Lipkin E, Balcer LJ, et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007; 69:2085-2092.
32. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59:1496-1506.
33. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75:706-710.
34. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59:679-687.
35. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56:1496-1504.
36. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-1497.
37. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, doubleblind, placebo-controlled trial. Ann Neurol 2007; 61:14-24.
38. Novartis. Novartis provides update on fingolimod phase III trial in primary progressive MS (PPMS). http://www.novartis.com/newsroom/media-releases/en/2014/1875463.shtml.
39. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63:1779-1787.
40. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Doublemasked trial of azathioprine in multiple sclerosis. British and Dutch multiple sclerosis azathioprine trial group. Lancet 1988; 2:179-183.
41. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27:591-605.
42. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446.
43. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40.
44. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MSSTAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383:2213-2221.
45. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9:681-688.
46. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12:857-865.
47. Vermersch P, Benrabah R, Schmidt N, et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 2012; 12:36.
48. Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010; 74:1033-1040.
49. Medicinova. SPRINT-MS: safety, tolerability and activity study of ibudilast in subjects with progressive multiple sclerosis: full text view: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01982942.
50. University College, London. MS-SMART: multiple sclerosis-secondary progressive multiarm randomisation trial-full text view-ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01910259.
51. Denic A, Johnson AJ, Bieber AJ, et al. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011; 18:21-29.
52. Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011; 17:81-88.
53. International progressive MS alliance. http://www.progressivemsalliance.org/.